Kyntra Bio Inc (KYNB)
Kyntra Bio Inc is a NASDAQ-listed common stock of a biotechnology company focused on developing and commercializing therapies for serious medical conditions with limited treatment options. Its pipeline includes FG-3246, an antibody-drug conjugate candidate aimed at CD46 for metastatic castration-resistant prostate cancer and other cancers, as well as roxadustat, a small-molecule HIF prolyl hydroxylase inhibitor that has completed Phase III development for anemia in chronic kidney disease and is also being studied for anemia associated with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. Formerly known as FibroGen, Inc., the company adopted the Kyntra Bio name in January 2026 and is headquartered in San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-KYNB
|
$9.09
|
23.3% Upside
|
Undervalued
|
$39
|
429.2% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
-0.5x
|
-0.7x
|
4.0x
|
28.499 M
|
-3.64 M
|
23.4%
|
88.0%
|
-46.4
|
—
|
37.8%
|
